PMID- 18655753 OWN - NLM STAT- MEDLINE DCOM- 20081114 LR - 20121115 IS - 1050-6586 (Print) IS - 1050-6586 (Linking) VI - 22 IP - 5 DP - 2008 Sep-Oct TI - The nasal decongestant effect of xylometazoline in the common cold. PG - 491-6 LID - 10.2500/ajr.2008.22.3202 [doi] AB - BACKGROUND: Xylometazoline is a nasal decongestant spray that constricts nasal blood vessels and increases nasal airflow, enabling patients with a blocked nose to breathe more easily. The purpose of this study was to characterize objectively and subjectively the decongestant and additional effects of xylometazoline in the common cold. METHODS: A double-blind, placebo-controlled, parallel group study was performed. Patients with a common cold (n = 61) were treated with xylometazoline 0.1% (n = 29) or placebo (saline solution; n = 32; 1 spray three times a day for up to 10 days). The primary objective was to determine the decongestant effect (nasal conductance); the secondary objectives were to determine the peak subjective effect (visual analog scale), duration of relief of nasal congestion, total and individual cold symptoms and general well-being (patients' daily diary), and adverse events (AEs). RESULTS: The decongestant effect of xylometazoline was significantly greater than placebo, as shown by the nasal conductance at 1 hour (384.23 versus 226.42 cm(3)/s; p